MAOB and Parkinson disease: Further alternative candidate protective mechanisms for xanthines and their derivatives include inhibition of the adenosine A2A receptor and the enzyme MAO-B, both of which are well-established PD drug targets with associated clinically approved drugs (e.g., the xanthine derivative drug Istradefylline, which targets A2A82, and the MAO inhibitor selegiline83).